Latest (77) Full Text Articles (1570) Focus on Biliary Tract Disease Article Summary

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial
Gastroenterology, 01/24/2014  Clinical Article

Zeuzem S, et al. – The authors performed a phase IIb, randomized, double–blind, placebo–controlled trial to evaluate the efficacy and safety of the combination of simeprevir, peginterferon–α2a (PegIFN), and ribavirin (RBV) in patients with hepatitis C virus (HCV) genotype–1 infection previously treated with PegIFN and RBV. In treatment–experienced patients, 12, 24, or 48 weeks simeprevir (100 mg or 150 mg once daily) in combination with 48 weeks PegIFN and RBV significantly increased rates of SVR at 24 weeks compared with patients given placebo, PegIFN, and RBV and was generally well tolerated.


  • The authors analyzed data from patients who did not respond (null response), had a partial response, or relapsed after treatment with PegIFN and RBV, randomly assigned to receive simeprevir (100 or 150 mg, once daily) for 12, 24, or 48 weeks plus PegIFN and RBV for 48 weeks (n = 396), or placebo plus PegIFN and RBV for 48 weeks (n = 66).
  • All patients were followed for 24 weeks after planned end of treatment; the primary end point was the proportion of patients with sustained virologic response (SVR; undetectable HCV RNA) at that time point.


  • Overall, rates of SVR at 24 weeks were significantly higher in the groups given simeprevir than those given placebo (61%-80% vs 23%; P < .001), regardless of prior response to PegIFN and RBV (simeprevir vs placebo: prior null response, 38%-59% vs 19%; prior partial response, 48%-86% vs 9%; prior relapse, 77%-89% vs 37%).
  • All groups had comparable numbers of adverse events; these led to discontinuation of simeprevir or placebo and/or PegIFN and RBV in 8.8% of patients given simeprevir and 4.5% of those given placebo.

► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from PDR - powered by MDLinx

Most Popular Gastroenterology Articles

Last month's top read Top Articles of 2014

1 A new virus in liver cancer Inserm (Institut national de la santé et de la recherche médicale), September 2, 2015

2 Liver failure treatment hope University of Edinburgh College of Medicine News, September 14, 2015

3 New guidelines address long-term needs of colorectal cancer survivors American Cancer Society News, September 10, 2015

4 Specific fatty acids may worsen Crohn's disease Duke University Health & Medicine News, September 18, 2015

5 Pancreatic cancer subtypes discovered in largest gene expression analysis of the disease to-date UNC Health Care System, September 10, 2015

6 Colorful potatoes may pack powerful cancer prevention punch Pennsylvania State University Health and Medicine News, August 28, 2015

7 FDA approves new oral medication to treat patients with advanced colorectal cancer Full Text FDA Press Announcements, September 23, 2015    Free full text

8 'Second brain' plays a role in gastrointestinal disorders with unknown causes KU Leuven News, September 21, 2015

9 A randomized trial comparing 4.8 vs. 2.4g/day of oral mesalazine for maintenance of remission in ulcerative colitis Digestive and Liver Diseases, September 21, 2015    Clinical Article

10 Researchers identify a new approach for lowering harmful lipids SUNY Downstate Medical Center News, September 8, 2015

11 Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients – a POCER study analysis Alimentary Pharmacology and Therapeutics, September 2, 2015    Clinical Article

12 Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial Gastroenterology, September 22, 2015    Clinical Article

13 Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial The Lancet, September 11, 2015    Clinical Article

14 Lemon juice and human norovirus German Cancer Research Center News, August 26, 2015

15 Potential new therapeutic approach found for liver cell cancer Medical University of Vienna, September 16, 2015

16 Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease Gastroenterology, September 17, 2015    Clinical Article

17 The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab Alimentary Pharmacology and Therapeutics, September 16, 2015    Review Article

18 Rosacea, use of tetracycline, and risk of incident inflammatory bowel disease in women Clinical Gastroenterology and Hepatology , September 29, 2015    Clinical Article

19 Hepatitis C virus infection is associated with increased cardiovascular mortality: A meta-analysis of observational studies Gastroenterology, September 22, 2015    Evidence Based Medicine

20 Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease Alimentary Pharmacology and Therapeutics, September 28, 2015    Clinical Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Other Topics in Gastroenterology

Register now to view all our site's content (FREE)!

View Samples and Register